SEAGEN
Seattle Genetics is a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a... humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1997 and is headquartered in Bothell, Washington.
SEAGEN
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
1998-01-01
Address:
Bothell, Washington, United States
Country:
United States
Website Url:
http://www.seagen.com
Total Employee:
1001+
Status:
Active
Contact:
6192707227
Email Addresses:
[email protected]
Total Funding:
1.74 B USD
Technology used in webpage:
Content Delivery Network IPv6 Microsoft Azure DNS ReCAPTCHA V2 Microsoft ASP.NET Ajax Google Cloud Global Multi-Region Google Analytics IP Anonymization Google Cloud CDN Level 3 Communications
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2018-01-31 | Cascadian Therapeutics | Cascadian Therapeutics acquired by Seagen | 614 M USD |
Investors List
Merck
Merck investment in Post-IPO Equity - Seagen
Takeda
Takeda investment in Post-IPO Equity - Seagen
New Enterprise Associates
New Enterprise Associates investment in Post-IPO Equity - Seagen
Sofinnova Investments
Sofinnova Investments investment in Venture Round - Seagen
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2015-06-11 | Cogent Biosciences | Seagen investment in Series B - Cogent Biosciences | 65 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-01 | Seagen Appoints Lee Heeson as Executive Vice President, Commercial International |
Official Site Inspections
http://www.seagen.com Semrush global rank: 746.98 K Semrush visits lastest month: 54.08 K
- Host name: 172.64.153.181
- IP address: 172.64.153.181
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Seagen"
Seagen - Pfizer
With the addition of Seagen, a world-leader in antibody-drug conjugates (ADCs), we will be at the forefront of cancer care. Together, we will bring new hope to patients everywhere. ... as we …See details»
Seagen - Wikipedia
Seagen Inc. (formerly Seattle Genetics, Inc.) is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington (a suburb of Seattle), is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the tar…See details»
Seagen25
Join us in celebrating Seagen’s rich 25-year history with stories of meaningful moments in our mission to transform the cancer care landscape and impact the future of oncology innovation. …See details»
Pfizer Completes Acquisition of Seagen
Dec 14, 2023 Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion. ... as we bring …See details»
Seagen - Crunchbase Company Profile & Funding
Organization. Seagen . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Seagen closed its last …See details»
Seagen - LinkedIn
Seagen | 98,208 followers on LinkedIn. Seagen is now part of Pfizer! Together with our Pfizer colleagues, we will continue our mission of bringing life-saving treatments to people living with cancer.See details»
Seagen - Dedicated to revolutionizing cancer care
Seagen is a global biotechnology company dedicated to revolutionizing cancer care. We’re developing transformative therapies that make a meaningful difference in people’s lives. Our …See details»
Seagen Org Chart + Executive Team - The Official Board
Jan 13, 2025 Organizational Chart of Seagen. Seagen Org Chart www.seagen.com. has 3 executives - and belongs to Pfizer +1 425 527 4000; Add an executive. Seagen (SGEN) News . Anything missing? We search for …See details»
Seagen Inc. Company Profile | Bothell, WA - Dun & Bradstreet
Company Description: Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. It is commercializing ADCETRIS for the treatment of several …See details»
Seagen Company Profile - Office Locations, Competitors ... - Craft
Seagen (formerly known as Seattle Genetics) is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Its products include ADCETRIS, for the …See details»
Pfizer Completes Acquisition of Seagen - Business Wire
Dec 14, 2023 Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company thaSee details»
Advancing Oncology Innovation: Celebrating One Year of Pfizer
Dec 20, 2024 Pfizer retained many colleagues at legacy Seagen, more than 2,500 colleagues across its Oncology organization, including major research and development sites in Bothell, …See details»
Pfizer Completes Acquisition of Seagen - Life Sciences British …
Dec 14, 2023 Seagen is a world-leader in ADC technology, a transformative modality that is emerging as a powerful tool across a broad range of cancers designed to preferentially kill …See details»
Seagen Company Profile -Sales, Contacts, Competitors – Buzzfile
This organization has been operating for approximately 28 years. Seagen is estimated to generate $2.0 billion in annual revenues, and employs approximately 3,083 people at this …See details»
Bothell-Based Seagen to Be Acquired by Pfizer in $43B Deal
Mar 14, 2023 Pfizer will acquire Seagen in a transaction worth $43 billion. Pfizer’s cancer treatment-focused organization Pfizer Oncology currently has a portfolio of 24 approved …See details»
Pfizer Receives All Required Regulatory Approvals to Complete the ...
Dec 12, 2023 Expects to close Seagen acquisition on December 14, 2023 Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and …See details»
Seagen - FinTech Magazine
Seagen, founded in 1998, is a biotechnology company dedicated to developing and commercialising transformative cancer therapies. By leveraging its proprietary antibody-drug …See details»
Seagen Inc Company Profile - Overview - GlobalData
Seagen Inc (Seagen), formerly Seattle Genetics Inc, is a biotechnology company focused on the discovery, development, and commercialization of monoclonal antibody-based therapies for …See details»
Seagen International GmbH - Swiss Biotech
Seagen International GmbH is the base for international operations of Seagen Inc., a global biotechnology company that discovers, develops and commercializes transformative cancer …See details»
SEAGEN: On Global Biotech Expansion and Advancing Oncology …
Aug 24, 2021 SEAGEN is a US-based global top 10 biotechnology company measured by market cap. The 20 years old company is focused exclusively on discovering, developing and …See details»